"Neoplasm, Residual" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Remnant of a tumor or cancer after primary, potentially curative therapy.
| Descriptor ID |
D018365
|
| MeSH Number(s) |
C04.697.700 C23.550.727.700
|
| Concept/Terms |
Neoplasm, Residual- Neoplasm, Residual
- Residual Neoplasms
- Residual Neoplasm
- Minimal Residual Disease
- Minimal Disease, Residual
- Residual Minimal Disease
- Residual Minimal Diseases
- Residual Disease, Minimal
- Minimal Residual Diseases
Residual Tumor- Residual Tumor
- Residual Tumors
- Residual Tumour
- Residual Tumours
- Tumour, Residual
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm, Residual".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm, Residual".
This graph shows the total number of publications written about "Neoplasm, Residual" by people in this website by year, and whether "Neoplasm, Residual" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 1 | 9 | 10 |
| 1996 | 1 | 7 | 8 |
| 1997 | 1 | 7 | 8 |
| 1998 | 4 | 4 | 8 |
| 1999 | 2 | 12 | 14 |
| 2000 | 0 | 10 | 10 |
| 2001 | 0 | 4 | 4 |
| 2002 | 1 | 3 | 4 |
| 2003 | 4 | 11 | 15 |
| 2004 | 4 | 7 | 11 |
| 2005 | 2 | 6 | 8 |
| 2006 | 4 | 17 | 21 |
| 2007 | 7 | 11 | 18 |
| 2008 | 1 | 8 | 9 |
| 2009 | 3 | 15 | 18 |
| 2010 | 8 | 8 | 16 |
| 2011 | 3 | 18 | 21 |
| 2012 | 4 | 17 | 21 |
| 2013 | 7 | 13 | 20 |
| 2014 | 11 | 14 | 25 |
| 2015 | 8 | 22 | 30 |
| 2016 | 8 | 22 | 30 |
| 2017 | 9 | 16 | 25 |
| 2018 | 8 | 16 | 24 |
| 2019 | 8 | 22 | 30 |
| 2020 | 5 | 18 | 23 |
| 2021 | 8 | 22 | 30 |
| 2022 | 1 | 30 | 31 |
| 2023 | 1 | 14 | 15 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm, Residual" by people in Profiles.
-
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024 Apr; 99(4):586-595.
-
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024 Feb 01; 143(5):417-421.
-
Characterization of residual cancer by comparison of a pair of organoids established from a patient with esophageal squamous cell carcinoma before and after neoadjuvant chemotherapy. Hum Cell. 2024 Mar; 37(2):491-501.
-
Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study. Blood. 2023 12 14; 142(24):2069-2078.
-
Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study. Clin Lymphoma Myeloma Leuk. 2024 03; 24(3):e59-e66.e2.
-
HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low category. Hum Pathol. 2023 Dec; 142:34-41.
-
Transforming ovarian cancer care by targeting minimal residual disease. Med. 2023 11 10; 4(11):755-760.
-
Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. J Clin Oncol. 2024 Jan 10; 42(2):218-227.
-
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2023 09 12; 7(17):4748-4759.
-
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. Ann Oncol. 2023 10; 34(10):899-906.